Trial Profile
A Phase II, Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients With Activating Epidermal Growth Factor Receptor Mutation in Circulating Tumor DNA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LiquidLung-A
- 01 Aug 2021 Status changed from active, no longer recruiting to completed.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2016 Status changed from not yet recruiting to recruiting.